Macro Finance
Lilly Buying Spree Surpasses $32B
Bloomberg Markets·November 18, 2026·1 min read
Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. The acquisition was reported by Bloomberg's Madison Muller on "Bloomberg Deals."
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.